Does TOFACITINIB Cause Injection site discolouration? 9 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Injection site discolouration have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.0% of all adverse event reports for TOFACITINIB.
9
Reports of Injection site discolouration with TOFACITINIB
0.0%
of all TOFACITINIB reports
0
Deaths
0
Hospitalizations
How Dangerous Is Injection site discolouration From TOFACITINIB?
Of the 9 reports.
Is Injection site discolouration Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does TOFACITINIB Cause?
Drug ineffective (30,382)
Pain (21,659)
Condition aggravated (16,925)
Arthralgia (15,640)
Fatigue (13,551)
Rheumatoid arthritis (12,277)
Off label use (11,736)
Headache (11,061)
Joint swelling (10,686)
Malaise (9,040)
What Other Drugs Cause Injection site discolouration?
ETANERCEPT (1,846)
DUPILUMAB (779)
CERTOLIZUMAB PEGOL (597)
ADALIMUMAB (554)
EVOLOCUMAB (476)
GLATIRAMER (270)
EXENATIDE (266)
TERIPARATIDE (249)
ASFOTASE ALFA (243)
ENBREL (231)
Which TOFACITINIB Alternatives Have Lower Injection site discolouration Risk?
TOFACITINIB vs TOFERSEN
TOFACITINIB vs TOLNAFTATE
TOFACITINIB vs TOLODODEKIN ALFA
TOFACITINIB vs TOLTERODINE
TOFACITINIB vs TOLVAPTAN